Davis, CA, United States of America

Heike Wulff

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 3.5

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Irvine, CA (US) (2004 - 2010)
  • Davis, CA (US) (2009 - 2024)

Company Filing History:


Years Active: 2004-2024

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: Heike Wulff: Innovator in Neuroprotective Compositions

Introduction

Heike Wulff is a prominent inventor based in Davis, CA (US). He has made significant contributions to the field of neuroprotective compositions, holding a total of 11 patents. His work focuses on developing methods to treat neurodegenerative diseases, showcasing his commitment to advancing medical science.

Latest Patents

Wulff's latest patents include innovative neuroprotective compositions and methods for their use. One notable invention is directed towards neuroprotective compositions aimed at treating neurodegenerative diseases. Another significant patent involves selective activators of the intermediate conductance CA2+ activated K+ channel KCa3.1, which includes benzoxazole and indole type KCa3.1 activators. These compounds have therapeutic uses in both human and animal subjects, as well as applications in the ex vivo preservation of organs or tissues.

Career Highlights

Throughout his career, Heike Wulff has worked with esteemed institutions such as the University of California and Louisiana State University and Agricultural & Mechanical College. His research has been pivotal in the development of new therapeutic strategies for neurodegenerative conditions.

Collaborations

Wulff has collaborated with notable colleagues, including K George Chandy and Nichole Coleman, who have contributed to his research endeavors.

Conclusion

Heike Wulff's innovative work in neuroprotective compositions and his collaborations with leading researchers highlight his significant impact on the field of medical science. His contributions continue to pave the way for advancements in treating neurodegenerative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…